We provide the latest news
from the world of economics and finance
(RTTNews) - Outlook Therapeutics, Inc. (OTLK) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has given a positive opinion on the approval of a new ophthalmic formulation of bevacizumab called ONS-5010/Lytenava also known as 'bevacizumab gamma.'
This new formulation is specifically designed to treat wet age-related macular degeneration or wet AMD in the European Union.
The CHMP's positive opinion was influenced by the outcomes of Outlook Therapeutics' wet AMD clinical program for ONS-5010, which included three successful registration clinical trials.
If authorized, ONS-5010 is anticipated to receive ten years of exclusive market rights in the European Union.
The company stated that it is also exploring direct sales and partnerships in Europe.
A decision from the European Commission is expected around 67 days after the CHMP opinion.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.